2022
DOI: 10.1200/jco.2022.40.16_suppl.12004
|View full text |Cite
|
Sign up to set email alerts
|

A phase III, randomized, sham-controlled trial of acupuncture for treatment of radiation-induced xerostomia (RIX) in patients with head and neck cancer: Wake Forest NCI Community Oncology Research Program Research Base (WF NCORP RB) trial WF-97115.

Abstract: 12004 Background: The majority of head/neck (HN) patients who undergo radiotherapy develop RIX. Unfortunately, existing treatments are of limited benefit and have side effects. Initial small studies suggest acupuncture may treat chronic RIX. A multicenter, phase III, randomized, sham-controlled trial (NCT02589938) was conducted to compare true acupuncture (TA) with sham acupuncture (SA) and wait list control (WLC) group in treating chronic RIX. Methods: HN patients with chronic RIX at least 12 months post-RT … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2022
2022
2025
2025

Publication Types

Select...
4
1

Relationship

1
4

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 0 publications
0
2
0
Order By: Relevance
“…To our knowledge, there have been no phase 3, multicenter trials to examine the effects of acupuncture to treat chronic RIX. The present randomized, phase 3, blinded, sham-controlled, multicenter trial examined whether TA could symptomatically improve RIX in patients with head and neck cancer with moderate or severe RIX …”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…To our knowledge, there have been no phase 3, multicenter trials to examine the effects of acupuncture to treat chronic RIX. The present randomized, phase 3, blinded, sham-controlled, multicenter trial examined whether TA could symptomatically improve RIX in patients with head and neck cancer with moderate or severe RIX …”
Section: Introductionmentioning
confidence: 99%
“…The present randomized, phase 3, blinded, sham-controlled, multicenter trial examined whether TA could symptomatically improve RIX in patients with head and neck cancer with moderate or severe RIX. 25 …”
Section: Introductionmentioning
confidence: 99%